CML

(redirected from Chronic Myeloid Leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

CML

Capital Market Line

In the capital asset pricing model, a line that plots the extra return an investor expects for each change in the level of risk. Rational investors expect higher returns for riskier assets and the capital market line shows this graphically. A portfolio that accurately reflects the capital market line is considered a Markowitz efficient portfolio. The slope of the capital market line is a calculation of the equilibrium market price of risk. See also: Beta.
References in periodicals archive ?
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib Leuk Res 201236:10-11.
He noted that patients in the accelerated and blast phases of chronic myeloid leukemia have a worse prognosis and higher Gleevec resistance, compared with patients in the chronic phase of the disease.
Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
GlobalData has released its pharma report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players".
In many patients with chronic myeloid leukemia (CML) that's impervious to imatinib, the new compounds suppress the malignancy, two studies show.
Low-dose interferon-[alpha] is just as effective as high-dose therapy in the treatment of chronic myeloid leukemia, according to the results of the first randomized, controlled trial to compare interferon dosages for the patient population.
NEW YORK -- Pfizer Oncology will present updated data in chronic myeloid leukemia (CML) for its oral Abl and Src kinase inhibitor, BOSULIF([R])(bosutinib),12,3,4,5recently approved by the U.
com announces that a new market research report is available in its catalogue: PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
The market was dominated by chronic myeloid leukemia in 2010.

Full browser ?